• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

    9/8/25 9:00:28 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FOLD alert in real time by email

    PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarker endpoints from the PROPEL open-label extension (OLE) study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) at the International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan.

    The new analysis, "208-week efficacy and safety of cipaglucosidase alfa plus miglustat in patients with late-onset Pompe disease treated from PROPEL baseline: muscle function and biomarkers," was conducted on the 82 patients (62 ERT-experienced and 20 ERT-naïve) who were randomized to cipa+mig in PROPEL and who enrolled in the open label extension (OLE).

    Pombiliti + Opfolda is indicated in the U.S. for the treatment of adult patients with LOPD weighing ≥40 kg and who are not improving on their current ERT. In the U.S., Pombiliti + Opfolda is not indicated for patients naïve to ERT treatment. The data summarized below are from the ERT-experienced group in the OLE. Pulmonary function data from the PROPEL OLE will be presented separately at an upcoming conference.

    The mean age was 48.8 years and the median duration of prior ERT in the ERT-experienced cohort at PROPEL baseline was 7.5 years. In the ERT-experienced group, the measures of muscle function, muscle strength and biomarkers improved and/or were sustained out to 208 weeks. Mean change from PROPEL baseline to week 208 were as follows:

    • Percent predicted six-minute walk distance (6MWD), +2.3%;
    • Lower extremity manual muscle test (MMT) score, +1.6 points;
    • Gait-Stairs-Gowers-Chair (GSGC) score, +0.1 points;
    • PROMIS® physical function score, +1.2 points;
    • Serum creatine kinase (CK) levels, -160.0 serum CK; and,
    • Urine hexose tetrasaccharide (Hex4), -1.9 mmol/mol creatinine.

    No new safety signals were identified. Up to week 208, 41 patients experienced treatment-related treatment-emergent adverse events (TEAEs), leading to four cipa+mig discontinuations, and two patients experienced serious treatment-related TEAEs, leading to two cipa+mig discontinuations. One patient experienced a TEAE (worsening of Lewy body disease) unrelated to study treatment, which led to death; the patient had discontinued from the study prior to death.

    "Durability of effect is important for evaluating the impact of treatments for individuals with LOPD. In this new analysis assessing the long-term outcomes from the open label extension of PROPEL, the improvements in muscle function, muscle strength, and biomarkers observed in patients receiving Pombiliti and Opfolda were maintained for four years," said Priya Kishnani, MD, Chief, Division of Medical Genetics, Chen Family Distinguished Professor of Pediatrics, Chief, Division of Medical Genetics, Duke University Medical Center. 

    "This new analysis adds to the growing body of evidence supporting the compelling clinical profile of Pombiliti and Opfolda in ERT-experienced adults," said Jeff Castelli, PhD, Chief Development Officer, Amicus Therapeutics, Inc. "To observe these sustained improvements and stability in the patients in the open label extension at four years is very encouraging given the progressive nature of LOPD. We look forward to presenting long-term extension data across pulmonary measures soon and will continue to closely study Pombiliti and Opfolda as part of our commitment to make a meaningful difference in the lives of people living with late-onset Pompe disease."

    Other abstracts at ICIEM

    In addition to this analysis, the following abstracts related to Pombiliti + Opfolda based on Amicus studies were also presented at ICIEM:

    Abstract Title: Cipaglucosidase alfa and alglucosidase alfa enzymes have similar stability at neutral pH and can be stabilized with miglustat

    • Presenter: Filip Cosmanescu, Amicus Therapeutics Inc., Princeton, NJ, U.S.A.

    Abstract Title: Integrating clinical evidence on cipaglucosidase alfa plus miglustat and alglucosidase alfa via a multi-level network meta-regression

    • Presenter: William Kerr, Amicus Therapeutics Ltd, Marlow, U.K.

    Abstract Title: PROPEL Japan subpopulation: efficacy and safety of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in patients with late-onset Pompe disease

    • Presenter: Hiroshi Kobayashi, The Jikei University School of Medicine, Tokyo, Japan

    Abstract Title: ATB200-19: an open-label, expanded access study of the safety and effectiveness of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease in Japan

    • Presenter: Aya Narita, ISEIKAI International General Hospital, Osaka, Japan

    Abstract Title: PROPEL Australia subpopulation: efficacy and safety of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in patients with late-onset Pompe disease

    • Presenter: Michel Tchan, Westmead Hospital, Westmead, NSW, Australia

    The following abstract related to Pombiliti + Opfolda from a non-Amicus study was also presented at ICIEM:

    Abstract Title: Real World Study: Assessing the impact of switching from alpha-glucosidase to cipaglucosidase alfa with miglustat on disease progression in adults with Pompe disease

    • Lead author: Sara Lucas Del Pozo, National Hospital for Neurology and Neurosurgery, UCLH, London, U.K.
    • Presenter: Robin Lachmann, National Hospital for Neurology and Neurosurgery, UCLH, London, U.K.

    About the PROPEL Study

    PROPEL was a 52-week, double-blind randomized global study designed to assess the efficacy, safety, and tolerability of cipaglucosidase alfa-atga + miglustat compared to non-U.S. approved alglucosidase alfa + placebo (the comparator). The study enrolled 123 adult LOPD patients who still had the ability to walk and to breathe without mechanical ventilation.

    Patients enrolled in PROPEL were randomized 2:1 so that for every two patients randomized to be treated with cipaglucosidase alfa-atga + miglustat, one was randomized to be treated with the comparator. Of the patients enrolled in PROPEL, 77% were being treated with alglucosidase alfa (n=95) for at least 2 years at study entry and 23% had never been treated with any ERT (n=28). 117 of the 123 patients (>95%) completed the PROPEL study.

    Efficacy endpoints of the study included primary endpoint of change from baseline to week 52 in 6-minute walk distance (6MWD) for comparison of superiority and key secondary endpoint of change from baseline to week 52 in forced vital capacity (FVC). PROPEL did not achieve statistical significance for the primary endpoint of superiority in change from baseline to week 52 in 6MWD in the overall population. After 52 weeks, ERT-experienced patients treated with cipaglucosidase alfa-atga + miglustat (n=61) walked an estimated 17 meters (95% CI, 0.2, 33) farther than the comparator group (n=29). After 52 weeks, ERT-experienced patients treated with cipaglucosidase alfa-atga + miglustat (n=55) showed an estimated treatment difference of 3.5% (95% CI, 1.0, 6.0) in FVC compared with the comparator group (n=29).

    About the PROPEL Open-label Extension Study

    The Phase 3 open-label extension (OLE) study (ATB200-07) is a multicenter, international study designed to evaluate the long-term safety and efficacy of cipaglucosidase alfa-atga + miglustat in adult subjects with LOPD who completed the Phase 3 PROPEL Study (ATB200-03). Of the 118 patients treated in the OLE, 81 continued cipa+mig treatment from PROPEL (cipa+mig group; 61 ERT-experienced prior to PROPEL; 20 ERT-naïve) and 37 switched from alg+pbo to cipa+mig (switch group; 29 ERT-experienced; 8 ERT-naive).

    Efficacy endpoints of the study included primary endpoint of change from PROPEL baseline to approximately 4 years in 6-minute walk distance (6MWD), forced vital capacity (FVC), creatine kinase (CK) and hexose tetrasaccharide (Hex4) levels, patient-reported outcomes and safety.

    About Pombiliti + Opfolda

    Pombiliti® + Opfolda®, is a two-component therapy that consists of cipaglucosidase alfa-atga, a bis-M6P-enriched rhGAA that facilitates high-affinity uptake through the M6P receptor while retaining its capacity for processing into the most active form of the enzyme, and the oral enzyme stabilizer, miglustat, that's designed to reduce loss of enzyme activity in the blood.

    U.S. INDICATIONS AND USAGE

    POMBILITI in combination with OPFOLDA is indicated for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT).

    SAFETY INFORMATION

    HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS: Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available. If a severe hypersensitivity reaction occurs, POMBILITI should be discontinued immediately and appropriate medical treatment should be initiated. INFUSION-ASSOCIATED REACTIONS (IARs): If severe IARs occur, immediately discontinue POMBILITI and initiate appropriate medical treatment. RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS: Patients susceptible to fluid volume overload, or those with acute underlying respiratory illness or compromised cardiac or respiratory function, may be at risk of serious exacerbation of their cardiac or respiratory status during POMBILITI infusion. See PI for complete Boxed Warning. CONTRAINDICATION: POMBILITI in combination with Opfolda is contraindicated in pregnancy. EMBRYO-FETAL TOXICITY: May cause embryo-fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for at least 60 days after the last dose. Adverse Reactions: Most common adverse reactions ≥ 5% are headache, diarrhea, fatigue, nausea, abdominal pain, and pyrexia. Please see full PRESCRIBING INFORMATION, including BOXED WARNING, for POMBILITI (cipaglucosidase alfa-atga) LINK and full PRESCRIBING INFORMATION for OPFOLDA (miglustat) LINK.

    About Late-Onset Pompe Disease

    Late-onset Pompe disease is an inherited lysosomal disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to accumulation of glycogen in cells, which is believed to result in the clinical manifestations of Pompe disease. Late-onset Pompe disease can be severe and debilitating with progressive muscle weakness throughout the body that worsens over time, particularly skeletal muscles and muscles that control breathing.

    About Amicus Therapeutics

    Amicus Therapeutics (NASDAQ:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company's website at www.amicusrx.com, and follow on X and LinkedIn.

    NP-AT-ALL-00010825

    CONTACTS:

    Investors:

    Amicus Therapeutics

    Andrew Faughnan

    Vice President, Investor Relations

    [email protected]

    (609) 662-3809

    Media:

    Amicus Therapeutics

    Diana Moore

    Vice President, Corporate Communications

    [email protected]

    (609) 662-5079

    FOLD-G



    Primary Logo

    Get the next $FOLD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FOLD

    DatePrice TargetRatingAnalyst
    7/17/2025$108.00Equal-Weight → Overweight
    Morgan Stanley
    12/13/2024$17.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    9/6/2024$18.00Buy
    Jefferies
    5/30/2024$18.00Overweight
    Wells Fargo
    5/14/2024$13.00Neutral → Buy
    Guggenheim
    12/19/2023$15.00 → $20.00Equal-Weight → Overweight
    Morgan Stanley
    9/9/2022$14.00Equal-Weight
    Morgan Stanley
    4/13/2022$11.00Neutral
    Goldman
    More analyst ratings

    $FOLD
    SEC Filings

    View All

    SEC Form 10-Q filed by Amicus Therapeutics Inc.

    10-Q - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

    7/31/25 4:02:39 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

    7/31/25 7:01:06 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Amicus Therapeutics Inc.

    S-8 - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

    6/5/25 4:46:04 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Amicus Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Amicus Therapeutics from Equal-Weight to Overweight and set a new price target of $108.00

    7/17/25 7:51:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Amicus Therapeutics from Overweight to Equal-Weight and set a new price target of $12.00 from $17.00 previously

    12/13/24 7:53:22 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Amicus Therapeutics with a new price target

    Jefferies initiated coverage of Amicus Therapeutics with a rating of Buy and set a new price target of $18.00

    9/6/24 7:39:36 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

    PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarker endpoints from the PROPEL open-label extension (OLE) study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) at the International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan. The new analysis, "208-week efficacy and safety of cipaglucosidase alfa plus miglustat in patients with late-onset Pompe disease treated from PROPEL baseline: muscle function and biomarkers," was conducted on the 82 patients (62 ERT-experienced and 20 ERT-naïve) who were

    9/8/25 9:00:28 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025

    PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Cantor Global Healthcare Conference 2025 in New York, NY, on Wednesday, September 3, 2025, at 10:20 a.m. ETMorgan Stanley 23rd Annual Global Healthcare Conference 2025 in New York, NY on Tuesday, September 9, 2025, at 3:20 p.m. ET A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (NASDAQ:FOLD) is a

    8/29/25 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators

    NetworkNewsWire Editorial Coverage NEW YORK, Aug. 6, 2025 /PRNewswire/ -- As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population's increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose. Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for years. There are more than 30 million Americans who have a rare disease, so there is a growing need for accurate diagnoses and eff

    8/6/25 8:30:00 AM ET
    $AMGN
    $CTOR
    $FOLD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $FOLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Harford Simon N.R. covered exercise/tax liability with 12,529 shares, decreasing direct ownership by 6% to 214,898 units (SEC Form 4)

    4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

    8/25/25 7:39:56 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mcglynn Margaret G was granted 20,414 shares, increasing direct ownership by 29% to 91,550 units (SEC Form 4)

    4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

    6/6/25 4:59:48 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Raab Michael was granted 20,414 shares, increasing direct ownership by 21% to 115,857 units (SEC Form 4)

    4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

    6/6/25 4:58:48 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    Financials

    Live finance-specific insights

    View All

    $FOLD
    Leadership Updates

    Live Leadership Updates

    View All

    $FOLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates

    Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti® + Opfolda® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the quarter ended June 30, 2025. "We delivered strong second quarter growth of 18%, marking the seventeenth consecutive quarter of doub

    7/31/25 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025

    PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2025. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.co

    7/21/25 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates

    1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S. Maintaining 2025 Guidance for Galafold, Reflecting Strong Underlying Demand Updating 2025 Pombiliti + Opfolda Guidance with New Patient Starts Accelerating in 2H Adjusting 2025 Total Revenue Growth Guidance to 15-22% at CER Reiterating GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and c

    5/1/25 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

    Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most recently as a public company CFO in the biotechnology industry. Daphne Quimi has decided to retire and will remain an Amicus employee through the end of the year to ensure a smooth transition. "Th

    8/21/23 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors

    PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience to the Company's Board of Directors, having served in various leadership positions throughout her career and bringing extensive experience advancing therapies across all phases of drug development. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "On behalf of our Board of Directors, I am pleased to announce the appointment of Dr. Eiry Roberts to the Amicus

    6/14/21 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development

    Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization PHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced the appointment of Sébastien Martel as Senior Vice President of Strategy and Business Development. Mr. Martel will lead the Company's corporate strategy and business and corporate development endeavors. He will be a member of the Amicus senior leadership team. Mr. Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President

    5/6/21 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

    SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

    11/14/24 9:00:58 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Amicus Therapeutics Inc.

    SC 13G - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

    11/14/24 11:37:23 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

    SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

    11/14/24 9:31:54 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care